FDA Brief

Warning letters Animal

FDA warning letter to

Henan Lvyuan Pharmaceutical Co. Ltd.

High riskIssued Mar 26Posted Mar 31Center for Veterinary Medicine

FDA warns Henan Lvyuan Pharmaceutical over CGMP failures at its API plant, including water leaks and incomplete batch records.

What happened

FDA inspected the Henan, China API facility from September 22 to 26, 2025. Investigators found corrosion on tank pipe connections and water leaks in the warehouse and production and packaging areas, including puddles in the drug warehouse, a Class D packaging area, and a water distribution area. FDA also found master batch records missing critical time limits and material quantities and deficient separation between certain operations that creates cross-contamination risk.

What FDA found

  1. The company did not properly maintain facilities and equipment; FDA saw extensive corrosion on tank pipe connections and water leaks that puddled in the drug warehouse, a Class D packaging area, and a water distribution area.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. Master batch records for an API lacked critical processing details, including time limits and the quantity or weight of material to be added.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The company had deficient separation between certain operations, creating a significant risk of cross-contamination between different drugs.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA asks for a detailed risk assessment of water exposure on all API lots in U.S. distribution and within expiry, with customer notification or recall actions if needed; a facilities and equipment corrective action plan; an independent global review of production process design and documentation for all APIs; detailed master batch records; and a historical review of process deviations. The company must also commit not to distribute the affected drugs to the U.S. unless adequate separation is in place, and respond in writing within 15 working days.

Who should pay attention

  • drug manufacturers that use APIs from this firm
  • brands and compounders sourcing APIs from China
  • companies relying on this facility in U.S. drug applications

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk